Ustekinumab is administered by subcutaneous injection using a loading schedule at weeks 0 and 4, followed by maintenance dosing every 12-week maintenance interval. After subcutaneous dosing, the antibody is slowly absorbed, reaching a terminal elimination half-life of approximately about 3 weeks in the PHOENIX phase 3 program. This prolonged systemic exposure is explained, at least in part, by FcRn-mediated salvage that protects the antibody from lysosomal degradation. Subcutaneous bioavailability has been estimated at approximately 57%, consistent with the slow absorption and sustained serum concentrations that support infrequent maintenance dosing.

Shared p40 neutralization. At the molecular level, ustekinumab is a fully human IgG1 kappa monoclonal antibody that binds the IL-12p40 subunit, a structural component shared by both IL-12 (p35+p40 heterodimer) and IL-23 (p19+p40 heterodimer). Structural studies characterising a Fab/IL-12 co-crystal structure place the ustekinumab epitope in the D1 domain of p40, with mutational analysis identifying specific residues in D1 required for antibody binding. Because p40 is the common subunit, this single binding event provides dual recognition of IL-12 and IL-23 — explaining why a molecule originally designed to target IL-12 simultaneously modulates IL-23.

Receptor-mediated cytokine signaling blockade. The immediate functional consequence of p40 binding is steric prevention of cytokine engagement with IL-12Rβ1-containing receptor complexes on NK cells and T cells. IL-12 ordinarily signals through an IL-12Rβ1/IL-12Rβ2 heterodimeric receptor in which IL-12Rβ1 contacts p40; IL-23 similarly requires IL-12Rβ1 as its proximal receptor subunit before associating with IL-23R for intracellular signaling. Ustekinumab prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of both receptor assemblies — a single blocking event that simultaneously interrupts both cytokine axes at their shared receptor-proximal step.

Dual JAK–STAT pathway suppression. Preventing IL-12 from engaging its receptor abolishes downstream activation of STAT4, the transcription factor that drives T-bet expression and Th1 lineage commitment — the primary source of IFN-gamma production in adaptive immune responses. In parallel, preventing IL-23 from engaging IL-23R abolishes JAK2/TYK2-dependent phosphorylation of STAT3, which otherwise drives induction of RORgammat and Th17 lineage commitment, with consequent secretion of IL-17A, IL-17F, and IL-22. The net effect is simultaneous attenuation of both Th1-associated and Th17-associated effector cytokine outputs from a single upstream target.

Pathway selectivity and Fc considerations. Because ustekinumab targets soluble cytokine prior to receptor engagement, it cannot bind IL-12 or IL-23 that is already docked to receptor complexes on cell surfaces. This constrains the mechanism to cytokine neutralization and makes it unlikely to mediate Fc effector functions such as antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity. The drug therefore does not affect immune responses driven by other cytokines or unrelated cellular programs — a targeted axis inhibitor rather than a global immunosuppressant.

Clinical translation. The molecular events map onto outcomes across three approved indications. In psoriasis, suppression of IL-12-driven IFN-gamma and IL-23-driven IL-17A/IL-17F reduces the cytokine milieu that sustains epidermal keratinocyte activation and plaque formation; controlled trials demonstrated attainment of PASI 75 responses exceeding placebo at week 12. In Crohn disease, blockade of the p40 axis interrupts intestinal immune programs driven by Th1 and Th17 effectors, translating to induction of clinical response and remission in phase 3 trials. In psoriatic arthritis, attenuation of IL-23-driven Th17 biology reduces synovial inflammation. The ~3-week half-life enables the once-every-12-weeks maintenance schedule to sustain continuous pathway suppression across all three disease settings.